Study That Tests AD109 in Patients Taking GLP-1 Drugs
NCT06400615 on ClinicalTrials.gov · last registry update 2025-02-19
A small phase 2 — 40 participants, against a typical 110. The sponsor logged completion for 26 December 2024. Primary outcome, as filed: Primary Objective (Adverse Events).
- Status
- COMPLETED
- Phase
- P2
- Drug
- semaglutideOzempic, Rybelsus, Wegovy
- Sponsor
- Apnimed
- Sponsor type
- Industry
- Enrollment
- 40
- Started
- 2024-05-20
- Primary completion
- 2024-12-26 actual
Observed history
No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.
Primary outcome
Primary Objective (Adverse Events)
Conditions studied
OSA
Every field above is taken directly from the registry record. See all detected changes across the class, or the semaglutide page for this molecule’s full trial and approval history.